NasdaqCM - Delayed Quote USD

Optimi Health Corp. (OPTH)

2.4100 -0.1900 (-7.31%)

At close: October 30 at 4:00:00 PM EDT

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

GlobeNewswire 5d ago

OPTH
-7.31%
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia

GlobeNewswire 11d ago

OPTH
-7.31%
Optimi Health to Present at the ThinkEquity Conference

GlobeNewswire 24d ago

OPTH
-7.31%
Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial

PREMIUM
MT Newswires 1mo ago

OPTH
-7.31%
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

GlobeNewswire 1mo ago

OPTH
-7.31%
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

GlobeNewswire 1mo ago

OPTH
-7.31%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive 1mo ago

OPTH
-7.31%
LLY

CURA.TO
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

Benzinga 1mo ago

OPTH
-7.31%
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

GlobeNewswire 1mo ago

OPTH
-7.31%
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire 1mo ago

OPTH
-7.31%
Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances

Simply Wall St. 2mo ago

OPTH
-7.31%
Optimi Health Establishes Discretionary Equity Facility

GlobeNewswire 2mo ago

OPTH
-7.31%

U.S. markets closed

Optimi Health Corp. (OPTH)

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia

Optimi Health to Present at the ThinkEquity Conference

Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances

Optimi Health Establishes Discretionary Equity Facility